EGFRI-Induced Skin Rash
Cross-source consensus on EGFRI-Induced Skin Rash from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Other
Highlighted claims
- Skin rash is the most common and characteristic toxicity associated with EGFRI treatment. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFRI-related skin rash can impair quality of life, raise infection risk, and lead to changes or interruption of treatment. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFRI-related rash usually appears as papules and pustules in sebaceous gland-rich areas. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol
- EGFRI-related rash is often painful or itchy and usually develops within one to two weeks after therapy begins. — Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol